{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:14:52Z","timestamp":1791224092353,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The META-Analysis of Pathologic Myopia Study group proposed a new classification system for myopic maculopathy (MM) with pathologic myopia (PM) defined as MM equal to\/more serious than diffuse atrophy or the presence of plus lesions and myopic choroidal neovascularization (mCNV) defined as CNV in the eye with PM. However, CNV in elderly eyes with high myopia (HM) not meeting the PM definition (high-myopia CNV) are not classified as age-related macular degeneration (nAMD) or mCNV. This retrospective study included 39 eyes with high-myopia CNV, 20 eyes with mCNV, and 20 eyes with AMD. All patients were at least 40\u00a0years old. We compared the clinical characteristics and treatment outcomes among three groups. The high-myopia CNV group had significantly more CNV types, shorter axial length and fewer lacquer cracks (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001, respectively); larger baseline greatest linear dimension (<jats:italic>P<\/jats:italic>\u2009=\u20090.0002), more fellow-eye drusen (<jats:italic>P<\/jats:italic>\u2009=\u20090.0106), more men (<jats:italic>P<\/jats:italic>\u2009=\u20090.0029), and more treatments (24\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.0098) compared to the mCNV group. Compared with the nAMD group, the high-myopia CNV group was significantly younger (<jats:italic>P<\/jats:italic>\u2009=\u20090.0041), and had fewer CNV types (<jats:italic>P<\/jats:italic>\u2009=\u20090.0316), more lacquer cracks (<jats:italic>P<\/jats:italic>\u2009=\u20090.0079) and fewer drusen (affected-eye, <jats:italic>P<\/jats:italic>\u2009=\u20090.0006 and fellow-eye, <jats:italic>P<\/jats:italic>\u2009=\u20090.0222), and fewer treatments (24\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.0030). Because the CNV in elderly eyes with HM not meeting the PM definition is classified as combined mCNV and nAMD, the clinical and angiographic findings are critical to determine the treatment strategy.<\/jats:p>","DOI":"10.1038\/s41598-022-18074-2","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T10:02:49Z","timestamp":1660384969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characteristics of choroidal neovascularization in elderly eyes with high myopia not meeting the pathologic myopia definition"],"prefix":"10.1038","volume":"12","author":[{"given":"Kaori","family":"Sayanagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"issue":"9827","key":"18074_CR1","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","volume":"379","author":"IG Morgan","year":"2012","unstructured":"Morgan, I. G., Ohno-Matsui, K. & Saw, S. M. Myopia. Lancet 379(9827), 1739\u20131748. https:\/\/doi.org\/10.1016\/S0140-6736(12)60272-4 (2012).","journal-title":"Lancet"},{"issue":"8","key":"18074_CR2","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ophtha.2006.04.022","volume":"113","author":"A Iwase","year":"2006","unstructured":"Iwase, A. et al. Prevalence and causes of low vision and blindness in a Japanese adult population: The Tajimi Study. Ophthalmology 113(8), 1354\u20131362. https:\/\/doi.org\/10.1016\/j.ophtha.2006.04.022 (2006).","journal-title":"Ophthalmology"},{"issue":"5","key":"18074_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","volume":"159","author":"K Ohno-Matsui","year":"2015","unstructured":"Ohno-Matsui, K. et al. International photographic classification and grading system for myopic maculopathy. Am. J. Ophthalmol. 159(5), 877\u201383.e7. https:\/\/doi.org\/10.1016\/j.ajo.2015.01.022 (2015).","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"18074_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.22608\/APO.2018290","volume":"7","author":"T Yokoi","year":"2018","unstructured":"Yokoi, T. & Ohno-Matsui, K. Diagnosis and treatment of myopic maculopathy. Asia Pac. J. Ophthalmol. (Phila). 7(6), 415\u2013421. https:\/\/doi.org\/10.22608\/APO.2018290 (2018).","journal-title":"Asia Pac. J. Ophthalmol. (Phila)."},{"key":"18074_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","volume":"63","author":"K Ohno-Matsui","year":"2018","unstructured":"Ohno-Matsui, K. et al. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog. Retin. Eye Res. 63, 92\u2013106. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.10.005 (2018).","journal-title":"Prog. Retin. Eye Res."},{"issue":"11","key":"18074_CR6","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"CMG Cheung","year":"2017","unstructured":"Cheung, C. M. G. et al. Myopic choroidal neovascularization: Review, guidance, and consensus statement on management. Ophthalmology 124(11), 1690\u20131711. https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.028 (2017).","journal-title":"Ophthalmology"},{"issue":"5","key":"18074_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.5.5","volume":"62","author":"K Ohno-Matsui","year":"2021","unstructured":"Ohno-Matsui, K. et al. IMI pathologic myopia. Investig. Ophthalmol. Vis. Sci. 62(5), 5. https:\/\/doi.org\/10.1167\/iovs.62.5.5 (2021).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"7","key":"18074_CR8","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","volume":"110","author":"T Yoshida","year":"2003","unstructured":"Yoshida, T. et al. Myopic choroidal neovascularization: A 10-year follow-up. Ophthalmology 110(7), 1297\u20131305. https:\/\/doi.org\/10.1016\/S0161-6420(03)00461-5 (2003).","journal-title":"Ophthalmology"},{"issue":"3","key":"18074_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf, S. et al. RADIANCE: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3), 682-692.e2. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.023 (2014).","journal-title":"Ophthalmology"},{"issue":"6","key":"18074_CR10","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno, Y. et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR Study. Ophthalmology 122(6), 1220\u20131227. https:\/\/doi.org\/10.1016\/j.ophtha.2015.01.025 (2015).","journal-title":"Ophthalmology"},{"issue":"3","key":"18074_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00417-015-3076-1","volume":"254","author":"V Sarao","year":"2016","unstructured":"Sarao, V. et al. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: Long-term outcomes. Graefes Arch. Clin. Exp. Ophthalmol. 254(3), 445\u2013454. https:\/\/doi.org\/10.1007\/s00417-015-3076-1 (2016).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"7","key":"18074_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/IAE.0000000000002164","volume":"39","author":"Y Onishi","year":"2019","unstructured":"Onishi, Y. et al. Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia. Retina 39(7), 1289\u20131298. https:\/\/doi.org\/10.1097\/IAE.0000000000002164 (2019).","journal-title":"Retina"},{"issue":"15","key":"18074_CR13","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"NM Bressler","year":"2004","unstructured":"Bressler, N. M. Age-related macular degeneration is the leading cause of blindness. JAMA 291(15), 1900\u20131901. https:\/\/doi.org\/10.1001\/jama.291.15.1900 (2004).","journal-title":"JAMA"},{"issue":"5","key":"18074_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/IAE.0000000000001732","volume":"38","author":"RF Spaide","year":"2018","unstructured":"Spaide, R. F. Improving the age-related macular degeneration construct: A new classification system. Retina 38(5), 891\u2013899. https:\/\/doi.org\/10.1097\/IAE.0000000000001732 (2018).","journal-title":"Retina"},{"issue":"5","key":"18074_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide, R. F. et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127(5), 616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004 (2020).","journal-title":"Ophthalmology"},{"issue":"14","key":"18074_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"18074_CR17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"18074_CR18","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin, D. F. et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 119(7), 1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053 (2012).","journal-title":"Ophthalmology"},{"issue":"20","key":"18074_CR19","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin, D. F. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897\u20131908. https:\/\/doi.org\/10.1056\/NEJMoa1102673 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"18074_CR20","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119(12), 2357\u20132348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006 (2012).","journal-title":"Ophthalmology"},{"issue":"1","key":"18074_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1), 89\u201399. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.028 (2021).","journal-title":"Ophthalmology"},{"issue":"9","key":"18074_CR22","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies, M. C. et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: Data from an observational study. Ophthalmology 122(9), 1837\u20131845. https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.010 (2015).","journal-title":"Ophthalmology"},{"issue":"6","key":"18074_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ajo.2013.01.016","volume":"155","author":"L Chang","year":"2013","unstructured":"Chang, L. et al. Myopia-related fundus changes in Singapore adults with high myopia. Am. J. Ophthalmol. 155(6), 991\u2013999. https:\/\/doi.org\/10.1016\/j.ajo.2013.01.016 (2013).","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"18074_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","volume":"129","author":"R Klein","year":"2011","unstructured":"Klein, R. et al. Prevalence of age-related macular degeneration in the US population. Arch. Ophthalmol. 129(1), 75\u201380. https:\/\/doi.org\/10.1001\/archophthalmol.2010.318 (2011).","journal-title":"Arch. Ophthalmol."},{"issue":"8","key":"18074_CR25","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","volume":"117","author":"K Hayashi","year":"2010","unstructured":"Hayashi, K. et al. Long-term pattern of progression of myopic maculopathy: A natural history study. Ophthalmology 117(8), 1595\u20131611. https:\/\/doi.org\/10.1016\/j.ophtha.2009.11.003 (2010).","journal-title":"Ophthalmology"},{"key":"18074_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.preteyeres.2018.12.001","volume":"70","author":"K Ohno-Matsui","year":"2019","unstructured":"Ohno-Matsui, K. & Jonas, J. B. Posterior staphyloma in pathologic myopia. Prog. Retin. Eye Res. 70, 99\u2013109. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.12.001 (2019).","journal-title":"Prog. Retin. Eye Res."},{"issue":"7","key":"18074_CR27","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1167\/iovs.09-3493","volume":"51","author":"Y Ikuno","year":"2010","unstructured":"Ikuno, Y. et al. Ocular risk factors for choroidal neovascularization in pathologic myopia. Investig. Ophthalmol. Vis. Sci. 51(7), 3721\u20133725. https:\/\/doi.org\/10.1167\/iovs.09-3493 (2010).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"18074_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/257381","volume":"2013","author":"T Wakabayashi","year":"2013","unstructured":"Wakabayashi, T. et al. Aqueous concentrations of vascular endothelial growth factor in eyes with high myopia with and without choroidal neovascularization. J. Ophthalmol. 2013, 257381. https:\/\/doi.org\/10.1155\/2013\/257381 (2013).","journal-title":"J. Ophthalmol."},{"issue":"3","key":"18074_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","volume":"141","author":"JP Tong","year":"2006","unstructured":"Tong, J. P. et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am. J. Ophthalmol. 141(3), 456\u2013462. https:\/\/doi.org\/10.1016\/j.ajo.2005.10.012 (2006).","journal-title":"Am. J. Ophthalmol."},{"issue":"5","key":"18074_CR30","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1136\/bjo.87.5.570","volume":"87","author":"K Ohno-Matsui","year":"2003","unstructured":"Ohno-Matsui, K. et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br. J. Ophthalmol. 87(5), 570\u2013573. https:\/\/doi.org\/10.1136\/bjo.87.5.570 (2003).","journal-title":"Br. J. Ophthalmol."},{"issue":"8","key":"18074_CR31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/IAE.0b013e318174417a","volume":"28","author":"Y Ikuno","year":"2008","unstructured":"Ikuno, Y. et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina 28(8), 1124\u20131131. https:\/\/doi.org\/10.1097\/IAE.0b013e318174417a (2008).","journal-title":"Retina"},{"issue":"4","key":"18074_CR32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ajo.2015.07.017","volume":"160","author":"G Querques","year":"2015","unstructured":"Querques, G. et al. Lacquer cracks and perforating scleral vessels in pathologic myopia: A possible relationship. Am. J. Ophthalmol. 160(4), 759-766.e2. https:\/\/doi.org\/10.1016\/j.ajo.2015.07.017 (2015).","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"18074_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/bjophthalmol-2018-312015","volume":"103","author":"T Ishida","year":"2019","unstructured":"Ishida, T. et al. Possible connection of short posterior ciliary arteries to choroidal neovascularisations in eyes with pathologic myopia. Br. J. Ophthalmol. 103(4), 457\u2013462. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312015 (2019).","journal-title":"Br. J. Ophthalmol."},{"issue":"9827","key":"18074_CR34","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim, L. S. et al. Age-related macular degeneration. Lancet 379(9827), 1728\u20131738. https:\/\/doi.org\/10.1016\/S0140-6736(12)60282-7 (2012).","journal-title":"Lancet"},{"key":"18074_CR35","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/CIA.S143508","volume":"12","author":"WM Al-Zamil","year":"2017","unstructured":"Al-Zamil, W. M. & Yassin, S. A. Recent developments in age-related macular degeneration: A review. Clin. Interv. Aging. 12, 1313\u20131330. https:\/\/doi.org\/10.2147\/CIA.S143508 (2017).","journal-title":"Clin. Interv. Aging."},{"issue":"2","key":"18074_CR36","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1167\/iovs.16-20652","volume":"58","author":"T Yokoi","year":"2017","unstructured":"Yokoi, T. et al. Parapapillary diffuse choroidal atrophy in children is associated with extreme thinning of parapapillary choroid. Investig. Ophthalmol. Vis. Sci. 58(2), 901\u2013906. https:\/\/doi.org\/10.1167\/iovs.16-20652 (2017).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"5","key":"18074_CR37","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1167\/iovs.18-25534","volume":"60","author":"E Corbelli","year":"2019","unstructured":"Corbelli, E. et al. Prevalence and phenotypes of age-related macular degeneration in eyes with high myopia. Investig. Ophthalmol. Vis. Sci. 60(5), 1394\u20131402. https:\/\/doi.org\/10.1167\/iovs.18-25534 (2019).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"4","key":"18074_CR38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1167\/iovs.18-25534","volume":"255","author":"M Ohnaka","year":"2017","unstructured":"Ohnaka, M. et al. A modified treat-and-extend regimen of aflibercept for treatment-na\u00efve patients with neovascular age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 255(4), 657\u2013664. https:\/\/doi.org\/10.1167\/iovs.18-25534 (2017).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18074-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:50:29Z","timestamp":1669359029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18074-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18074"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18074-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"9 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13795"}}